Waystar Holding Corp.(WAY) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, revenue reached $304 million, growing 24% year-over-year and 12% organically, with full-year revenue increasing 17% to $1.1 billion [21][22] - Adjusted EBITDA for Q4 was $129 million, up 29% year-over-year, with an adjusted EBITDA margin of 42.5%, exceeding the long-term target of 40% [10][24] - Unlevered free cash flow was $80 million in Q4 and $365 million for the full year, converting 79% of adjusted EBITDA to unlevered free cash flow [25] Business Line Data and Key Metrics Changes - Subscription revenue for Q4 was $168 million, increasing 38% year-over-year, while volume-based revenue was $134 million, up 11% year-over-year [23] - For the full year, subscription revenue totaled $558 million, a 22% increase, and volume-based revenue reached $535 million, also up 11% year-over-year [24] Market Data and Key Metrics Changes - Waystar added 85 clients with trailing twelve-month spend above $100,000 in Q4, up from 30 a year ago, indicating strong market demand [9] - The company achieved a Net Revenue Retention rate of 112% and a Gross Revenue Retention rate of 97% [9][22] Company Strategy and Development Direction - The acquisition of Iodine Software expanded Waystar's addressable market and client base, adding over 1,000 hospitals and health systems [7][11] - Waystar aims to lead in AI-powered revenue cycle automation, with approximately 50% of its solutions leveraging AI [14][20] - The company is focused on delivering a fully autonomous revenue cycle, integrating clinical and financial data to enhance operational efficiency [12][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the business model, anticipating continued low double-digit revenue growth [10][26] - The company expects revenue for 2026 to be between $1.274 billion and $1.294 billion, representing a 17% year-over-year growth [26][28] - Management highlighted strong customer confidence and a robust sales pipeline entering 2026 [10][27] Other Important Information - Waystar's partnership with Google Cloud's Gemini LLM is expected to accelerate innovation in AI capabilities [16] - The company is committed to maintaining a leverage ratio at or below 3x and continuing to reinvest in growth opportunities [25][29] Q&A Session Summary Question: AI and customer appetite for LLMs - Management noted that most clients prefer integrating AI capabilities into existing systems rather than building their own, highlighting a trend towards trusted partnerships in AI deployment [31][41] Question: New AI agents and revenue opportunities - New AI agents are expected to provide both incremental revenue opportunities and enhance the existing AI offerings, contributing to client retention and value [42][44] Question: Cost structure and margin guidance - The increase in G&A, R&D, and SG&A costs is attributed to the inclusion of Iodine, with expectations for continued margin improvement through cost synergies [47][49] Question: AI market growth in healthcare - Management sees significant opportunities in AI within healthcare, emphasizing the need for secure, scalable, and accurate solutions [60][62] Question: Patient utilization assumptions for 2026 - Management expects patient utilization to remain healthy, aligning with historical trends and supporting revenue growth [66] Question: Impact of high-deductible health plans on patient volumes - There was a sequential decrease in patient volumes as patients met their deductibles, but this was offset by growth in provider solutions [70][72] Question: Competitive landscape and ROI - Management emphasized the compelling ROI of their platform compared to point solutions, noting strong win rates and client preference for integrated solutions [83][84]